September 10, 2025Scientific ReportsOpen Access

Real-world study of first-line immunotherapy combined with chemoradiotherapy in esophageal squamous cell carcinoma

View Full Paper

Ask AI

Bookmark

Authors

XZXiaohan ZhaoTianjin University of Commerce CWCekai WengGuangdong Provincial People's Hospital WYWuhan YangHebei Medical University

Discussion

Member takes

Implication

Retrospective analysis shows improved overall survival and safety in esophageal squamous cell carcinoma, suggesting effective first-line treatment strategies.

Key Points

Immunotherapy combined with chemoradiotherapy resulted in strong anti-tumor activity and tolerability for ESCC patients.
Objective response rate reached 82.3%, with progressive-free survival at a median of 14.6 months.
Factors like immunotherapy cycles and radiation coverage significantly impacted overall survival outcomes.
A notable 46.8% of patients faced treatment failure, indicating the necessity of large-scale randomized controlled trials.

Cite This Study

Zhao et al. (2025) studied this question.

synapsesocial.com/papers/68c240deb210217d6479d2da https://doi.org/10.1038/s41598-025-12250-w

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis shows improved overall survival and safety in esophageal squamous cell carcinoma, suggesting effective first-line treatment strategies.

Real-world study of first-line immunotherapy combined with chemoradiotherapy in esophageal squamous cell carcinoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Real-world study of first-line immunotherapy combined with chemoradiotherapy in esophageal squamous cell carcinoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider